Catalan Medical Technology to treat the Pectus Excavatum

Pectus Excavatum is the most common chest congenital deformity, since it represents a 95% of the total cases. It is characterized by a depression of the breastbone (sternum) that sinks the thorax, and it is also known as funnel chest. The deformity is diagnosed in newborns and it gradually develops during puberty. It is estimated that this chest deformity occurs in one of each 500-100 births and it is more common in male patients (male to female ratio being 3 to 1).

Taulinoplastia with Pectus Up Surgery Kit

Only a few years back, treatments for the Pectus Excavatum were very aggressive for the patient. In 2012, Ventura Medical Technologies, along with the hospital Corporació Sanitària Parc Taulí from Sabadell (Barcelona), developed a new surgical method named Taulinoplastia offering an extrathoracic minimally invasive approach to fix this pathology. Ventura Medical Technologies developed the implant and the tool needed to perform the Taulinoplastia: the Pectus up Surgery Kit.

Taulinoplastia is an important technological innovation in the world of thoracic surgery for the Pectus Excavatum treatment. It is a minimally invasive method considerably reducing risks and complexity of the intervention, which carries a shorter recovery time for the patient and very satisfactory results. Patients with Pectus Excavatum having been operated on with this new method emphasize the slight pain and the quick return to their everyday life.

Benefits of the Taulinoplastia with the Pectus Up Surgery Kit

▪Minimally invasive: only a small incision is made to insert the implant.

▪Extrathoracic procedure: the implant is inserted into subcutaneous tissue.

▪Minimal blood loss: a single incision is made and, being extrathoracic, the patient does not suffer blood loss as in other reconstructive surgery procedures.

▪No risk of intrathoracic organs damage: the used method does not insert any material into the thorax, so there is no risk of damaging vital organs.

▪Brief surgical intervention: the complexity of the operation is reduced.

▪Short hospital stay: as it is a less severe intervention, patients stay few days in hospital.

▪Intermediate care postoperative period: as it is a fairly noninvasive method, patients do not need ICU care.

▪Decrease in problems related to Pectus Excavatum: pathologies associated with the deformity evolution are prevented.

▪Growth adaptation: the ribcage bone growth is not limited and a normal development is allowed without modifying or removing the implant.

Cases in Spain

Taulinoplastia has already been established in Spain, where several surgeons have started operating on patients with the Pectus Up Surgery Kit, after being relevantly trained.

Since April 2016, actual start of the commercialization, and the first months of 2017, 30Pectus Excavatum cases have been treated through the Taulinoplastia technique in Spain. Barcelona, Valladolid and Madrid are the Spanish cities where several patients have already been operated on with this new method.

Surgeries have been performed in the following hospitals:

-Hospital Parc Taulí (Sabadell)

-Hospital Vall d’Hebron (Barcelona)

-Hospital Universitari Sagrat Cor (Barcelona)

-Hospital Universitari General de Catalunya (Barcelona)

-Centro Médico Teknon (Barcelona)

-Clínica Diagonal (Barcelona)

-Hospital de Barcelona

-Hospital Clínico (Valladolid)

-Fundación Universitaria Jiménez Díaz (Madrid)

-Hospital Rey Juan Carlos I (Móstoles, Madrid)

Internationalization

Taulinoplastia is beginning to be used in Europe. France is the first country practicing this new technique, specifically in Centre Hospitalier Universitaire-CHU de Saint-Étienne.

Commercialization of Pectus Up is envisaged in United Kingdom, Italy and Portugal during this year 2017.

In turn, Taulinoplastia will also be established in a short time period in Latin America, particularly in Colombia, Mexico and Costa Rica, where this product is undergoing registration process.

Accreditations

The Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) in Spain; The Agence Nationale de Sécurité du Medicament et des Produits de Santé (ANSM) in France; The Regulatory Agency Medicines and Healthcare products Regulatory Agency (MHRA) in UK, and the Autoridade Nacional do Medicamento e Produtos de Saude I.P. (INFARMED) in Portugal have authorized Ventura Medical Technologies to commercialize the Pectus Up Surgery Kit.